Terns Pharmaceuticals announced significant updates regarding TERN-601, a novel oral GLP-1R agonist, following a successful Phase 1 clinical study and the completion of enrollment in its Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback